March 04, 2026 — 41 articles reviewed
This cycle’s coverage clustered around two poles of the age spectrum, with a single study in Pediatrics reinforcing that even infrequent adolescent cannabis use carries measurable harm, while a separate study found no link between cannabis use and cognitive decline in older adults. Beyond the clinical data, pharmaceutical standardization milestones, Phase 3 trial progress for CBD and insomnia, evolving legal protections, and persistent policy gridlock rounded out a dense 24 hours.
When the same 24 hours deliver evidence that occasional teenage use causes harm and that older adult use does not accelerate cognitive decline, the message is not contradictory but rather precise: the biology of who is using cannabis matters as much as whether they are using it, and that distinction should be driving every clinical conversation we have.
Digest-Level Clinical Commentary
Clinical Reflection
The convergence of pediatric safety data with advancing pharmaceutical standardization and Phase 3 trial progression suggests we’re transitioning from anecdotal cannabis medicine toward evidence-based protocols with defined dosing and age-appropriate applications. The adolescent findings reinforce what we’re learning across the lifespan: that frequency and developmental timing matter significantly for clinical outcomes, which should inform how we counsel patients and their families about realistic therapeutic windows. This maturation of the evidence base means my practice can increasingly move beyond managing patient expectations around unproven claims and toward specific, condition-targeted recommendations supported by reproducible data.
Clinical Perspective
Recent cannabis-related literature continues to reflect growing clinical interest in cannabinoid therapeutics, particularly CBD for specific indications such as insomnia, supported by advancing Phase 3 trial data. Concurrent attention to pediatric safety concerns underscores the importance of age-stratified evidence, as emerging data suggests potential risks even with infrequent adolescent use. The parallel focus on pharmaceutical standardization represents a necessary shift toward reproducible dosing and formulation consistency that supports clinical translation and regulatory pathways.
Pediatrics
ResearchRegulatoryCBDClinical Trials💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: